The field of protein degraders is at an inflection point as more degraders enter the clinical space. Evaluating the patent filing activity will play a critical role in the ability to managing opportunities for licensing and partnerships.
Bristol-Myers Squibb (BMY) Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The "Emerging Landscape of Targeted Protein Degradation Therapeutics" report has been added to ResearchAndMarkets.com s offering. Advancing.
/PRNewswire/ Biotheryx, Inc., a clinical stage company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs).